D.E. Shaw & Co
SGMT icon

D.E. Shaw & Co’s Sagimet Biosciences SGMT Stock Holding History

D.E. Shaw & Co’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Sell
22,177
-389,393
-95% -$2.65M ﹤0.01% 4576
2026
Q1 		$2.15M Sell
411,570
-73,926
-15% -$412K ﹤0.01% 2857
2025
Q4 		$2.87M Sell
485,496
-215,745
-31% -$1.55M ﹤0.01% 2756
2025
Q3 		$4.81M Buy
701,241
+557,393
+387% +$4.52M ﹤0.01% 2239
2025
Q2 		$1.1M Buy
+143,848
New +$607K ﹤0.01% 3173

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

D.E. Shaw & Co's SGMT Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Sagimet Biosciences (SGMT) stake by 95% in Q2 2026, selling an estimated $2.65M and leaving 22,177 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #4576.

D.E. Shaw & Co first reported a position in SGMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.81M in Q3 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • D.E. Shaw & Co held 22,177 shares of Sagimet Biosciences worth $171K as of Q2 2026.
  • D.E. Shaw & Co sold 389,393 Sagimet Biosciences shares in Q2 2026, an estimated $2.65M.
  • Sagimet Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4576 holding.
  • D.E. Shaw & Co first reported a position in Sagimet Biosciences in Q2 2025 and has held it in 5 quarters since.
  • D.E. Shaw & Co's Sagimet Biosciences position peaked at $4.81M in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.